Glox Therapeutics

Glox Therapeutics is a pioneering company in the development of precision antibiotic therapies based on natural bacteriocins. Glox Therapeutics is leveraging engineered protein bacteriocins to develop precision antibiotics. These novel antimicrobial agents exhibit significant potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens that have already developed AMR, including Pseudomonas aeruginosa and Klebsiella pneumoniae. Bacteriocins, naturally produced by bacteria, possess antimicrobial properties against strains of the same or related species. Harnessing the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics.